{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:24:34Z","timestamp":1791221074562,"version":"4.1.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the safety and effectiveness of guanfacine extended release (GXR) administered concomitantly with psychostimulants in children and adolescents with attention-deficit\/hyperactivity disorder (ADHD) and suboptimal response to a psychostimulant alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Methods:<\/jats:title>\n                    <jats:p>This was a multicenter, open-label, 9-week, dose-escalation study of 75 subjects with ADHD treated with methylphenidate (MPH) or amphetamine (AMP) alone for at least 1 month, yet with suboptimal control of ADHD symptoms. Sixty-three subjects (84.0%) completed the study. Patients received GXR in addition to their psychostimulant. Starting with 1\u2009mg\/day, GXR was increased weekly to the highest tolerated dose (1, 2, 3, or 4\u2009mg\/day), which was maintained through week 6. GXR was then titrated downward in 1-mg weekly decrements from week 7 through week 9. Psychostimulant treatment regimens were continued until at least week 7.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures:<\/jats:title>\n                    <jats:p>Safety assessments included adverse events (AEs), vital signs, physical examination, clinical laboratory tests, the Pediatric Daytime Sleepiness Scale, and the Pittsburgh Side Effects Rating Scale. Efficacy was assessed using the ADHD Rating Scale IV (ADHD-RS-IV), the Conners' Parent Rating Scale\u2013Revised Short Form, Clinical Global Impressions, Parent Global Assessment, and Child Health Questionnaire\u2013Parent Form.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The most common treatment-related AEs were upper abdominal pain (25.3%), fatigue (24.0%), irritability (22.7%), headache (20.0%), and somnolence (18.7%). Most AEs were mild to moderate in severity. Investigator-rated AEs due to blood pressure decreases, heart rate, or electrocardiogram findings were infrequent. Mean changes from baseline (psychostimulant monotherapy just prior to receiving GXR) to end point in ADHD-RS-IV total score were statistically significant overall: \u221216.1 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Significant improvement in both subscales of the ADHD-RS-IV was observed. Improvement of symptoms was observed in a majority of subjects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Coadministration of GXR and MPH or AMP was generally safe and associated with statistically significant and clinically meaningful ADHD symptom improvement in children and adolescents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2008.0152","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T18:59:33Z","timestamp":1256929173000},"page":"501-510","source":"Crossref","is-referenced-by-count":88,"title":["Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1177","volume":"19","author":[{"given":"Thomas J.","family":"Spencer","sequence":"first","affiliation":[{"name":"Harvard Medical School and Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Greenbaum","sequence":"additional","affiliation":[{"name":"Capstone Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence D.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Red Oak Psychiatry Associates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Rory","family":"Murphy","sequence":"additional","affiliation":[{"name":"Psychiatric Associates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"e_1_3_3_2_1","volume-title":"Wayne","author":"Adderal XR","year":"2009","unstructured":"Adderal XR. (package insert). Wayne. Pennsylvania: Shire US Inc., 2009."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-006-0044-9"},{"key":"e_1_3_3_4_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Washington (DC): American Psychiatric Association."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0098"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66915-2"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-3695"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.9.1253"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454604773840571"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199608000-00008"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199509000-00010"},{"key":"e_1_3_3_12_1","unstructured":"Concerta (package insert). Titusville. New Jersey: McNeil Pediatrics 2009."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/000992280003900102"},{"key":"e_1_3_3_14_1","first-page":"15","article-title":"Clonidine for attention-deficit\/hyperactivity disorder: II. ECG changes and adverse events analysis","volume":"39","author":"Daviss WB","year":"2008","unstructured":"Daviss WB, , Patel NC, , Robb AS, , McDermott MP, , Bukstein OG, , Pelham WEJr, , Palumbo D, , Harris P, , Sallee FR. Clonidine for attention-deficit\/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry, 39:15\u201325. 2008.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199710001-00007"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200202001-00003"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000046908.27264.00"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1995.5.215"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199501000-00013"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.020"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.12.1793"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31815d9af7"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1995.5.157"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318191769e"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-4993(18)30106-8"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.7.1067"},{"key":"e_1_3_3_27_1","volume-title":"Guanfacine extended release tablets as treatment for attention-deficit\/hyperactivity disorder: formulation characteristics","author":"Shojaei AH","year":"2006","unstructured":"Shojaei AH, , Chang R-K, , Pennick M. Guanfacine extended release tablets as treatment for attention-deficit\/hyperactivity disorder: formulation characteristics. Poster presented at the U.S. Psychiatric & Mental Health Congress, November 16\u201319, 2006 New Orleans, Louisiana."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1995.5.301"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200102000-00011"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.04.016"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.4.527"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90299-6"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2008.0152","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2008.0152","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2008.0152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:54:36Z","timestamp":1777388076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2008.0152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1089\/cap.2008.0152"],"URL":"https:\/\/doi.org\/10.1089\/cap.2008.0152","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}